Analysts unshaken by patient death in BMS lung fibrosis trial
Analysts unshaken by patient death in BMS lung fibrosis trial
Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Princeton, New Jersey, USA
Founded:1887
Website:www.bms.com/
Recent News
BMS reports liver injury events in lung disease program, with key readout near
BMS reports liver injury events in lung disease program, with key readout near
BMS cuts another 265 jobs tied to New Jersey HQ
Bristol Myers Squibb plans to lay off another 265 employees tied to its corporate headquarters in New Jersey, bringing the number of total layoffs the company has announced this year in the Garden State to more than 700.
Sources quash rumours of an AZ/BMS mega-merger
Sources quash rumours of an AZ/BMS mega-merger
An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
Merger talks between AstraZeneca, Bristol Myers are off — report
Merger talks between AstraZeneca, Bristol Myers are off — report
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays. Reported by BioSpace on 2026-07-30.
BMS, NVIDIA to build 'most powerful' AI factory
BMS, NVIDIA to build 'most powerful' AI factory.
Bristol Myers to build 'powerful' AI factory; Samsung Biologics bids for peptide maker
Bristol Myers Squibb announced it would build a 'powerful' AI factory, while Samsung Biologics bids for peptide maker PolyPeptide.
Bristol Myers reaches a crossroads as a make-or-break year takes shape
Bristol Myers Squibb enters a pivotal year with multiple late-stage readouts and strategic decisions that could reshape its growth trajectory through the back half of the decade.
Leadership Team
Christopher Boerner, Ph.D.
Chairman and Chief Executive Officer
David Elkins
Chief Financial Officer